Key points
- Revenue increased by 19% to $34,865k
- EBITDA loss reduced significantly to $2,012k
- No dividends paid for the year
- Company entered into a $2.75 million loan facility
- Net assets decreased to $14,275k
Full summary
Nova EYE Medical Ltd has released its annual report for the financial year ending 30 June 2026. The company reported a 19% increase in revenues to $34,865k, up from $29,267k in the previous year. The EBITDA loss improved significantly, reducing from $5,462k to $2,012k, with a positive EBITDA result of $172k in the second half of the year. The operating loss after tax decreased to $4,333k from $9,059k. The company's AlphaRET segment, focused on the commercialization of the 2RT® ophthalmic laser, did not generate material revenues. The Glaucoma Surgical Devices segment reported sales of $34,865k, with an EBITDA loss of $709k. The company entered into a $2.75 million loan facility with River Street Nominees Pty Ltd, replacing a previous receivables facility agreement. The company's net assets decreased to $14,275k, and no dividends were paid during the year.
Guidance
EBITDA loss expected to improve in FY2027, revenue growth in Glaucoma Surgical Devices
Outlook
Nova EYE Medical Ltd expects to continue improving its financial performance in FY2027, with a focus on reducing the EBITDA loss and growing revenues from its Glaucoma Surgical Devices segment.